43 A patient centred evaluation of innovative ambulatory ECG monitoring

Hall, R. J.; John, Sophia; Monkhouse, Christopher; Rowland, Edward; Chow, Anthony; Behar, Jonathan M.

doi:10.1136/heartjnl-2019-bcs.41

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is evidence that the diagnostic yield for detecting underlying arrhythmia is highest when cardiac monitoring devices are applied early after syncope, ideally at the index visit1–3. To solve the problems with current routine ECG monitoring devices, several novel ambulatory devices have recently been developed1 12–15. These devices are non-invasive, water-resistant, have no leads or wires, are discreet to wear and are CE-marked for clinical use in the UK.…”

Section: Introductionmentioning

confidence: 99%

Multicentre open label randomised controlled trial of immediate enhanced ambulatory ECG monitoring versus standard monitoring in acute unexplained syncope patients: the ASPIRED study

et al. 2023

View full text Add to dashboard Cite

IntroductionDiagnosing underlying arrhythmia in emergency department (ED) syncope patients is difficult. There is a evidence that diagnostic yield for detecting underlying arrhythmia is highest when cardiac monitoring devices are applied early, ideally at the index visit. This strategy has the potential to change current syncope management from low diagnostic yield Holter to higher yield ambulatory monitoring, reduce episodes of syncope, reduce risk of recurrence and its potential serious consequences, reduce hospital admissions, reduce overall health costs and increase quality of life by allowing earlier diagnosis, treatment and exclusion of clinically important arrhythmias.Methods and analysesThis is a UK open prospective parallel group multicentre randomised controlled trial of an immediate 14-day ambulatory patch heart monitor vs standard care in 2234 patients presenting acutely with unexplained syncope. Our patient focused primary endpoint will be number of episodes of syncope at 1 year. Health economic evaluation will estimate the incremental cost per syncope episode avoided and quality-adjusted life year gained.Ethics and disseminationInformed consent for participation will be sought. The ASPIRED trial received a favourable ethical opinion from South East Scotland Research Ethics Committee 01 (21/SS/0073). Results will be disseminated via scientific publication, lay summary and visual abstract.Trial registration numberISRCTN 10278811.

show abstract

Section: Introductionmentioning

confidence: 99%